# EDGAR Filing Document

**Accession Number:** 0001787740
**File Stem:** 0001683168-25-005419
**Filing Date:** 2025-7
**Character Count:** 60907
**Document Hash:** 271d818b7395d28e595d7945862f41f9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001683168-25-005419.hdr.sgml**: 20250725

**ACCESSION NUMBER**: 0001683168-25-005419

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 6

**FILED AS OF DATE**: 20250725

**DATE AS OF CHANGE**: 20250725

**EFFECTIVENESS DATE**: 20250725

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Tivic Health Systems, Inc.
- **CENTRAL INDEX KEY:** 0001787740
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 814016391
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-288969
- **FILM NUMBER:** 251152242

**BUSINESS ADDRESS:**
- **STREET 1:** 47685 LAKEVIEW BLVD
- **CITY:** FREMONT
- **STATE:** CA
- **ZIP:** 94538
- **BUSINESS PHONE:** (888)276-6888

**MAIL ADDRESS:**
- **STREET 1:** 47685 LAKEVIEW BLVD
- **CITY:** FREMONT
- **STATE:** CA
- **ZIP:** 94538

**As filed with the Securities and Exchange Commission on July 25, 2025**

**Registration No. 333-** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT**

**UNDER**

**THE SECURITIES ACT OF 1933**

**Tivic Health Systems, Inc.**

(Exact name of Registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **81-4016391** |
| (State or other jurisdiction of<br> incorporation or organization) | (I.R.S. Employer<br> Identification Number) |

---

**47685 Lakeview Blvd.**

**Fremont, California 94538<br> (888) 276-6888**<br> (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

**Inducement Restricted Stock Unit Award**

(Full title of the plans)

**Jennifer Ernst<br> Chief Executive Officer<br> 47685 Lakeview Blvd.**

**Fremont, California 94538<br> (888) 276-6888**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

***Copies to*:**

**Christopher L. Tinen, Esq.**

**Caitlin M. Murphey, Esq.<br> Snell & Wilmer L.L.P.<br> 3611 Valley Centre Drive, Suite 500**

**San Diego, CA 92130**

**(858) 910-4809**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

**INTRODUCTION**

Tivic Health Systems, Inc. (the "Company," "we," "us," or "our") is filing this Registration Statement on Form S-8 (this "Registration Statement") for the purpose of registering an aggregate of 35,295 shares of common stock of the Company, par value $0.0001 per share ("Common Stock"), issuable upon vesting and settlement of restricted stock units ("RSUs") granted to Michael Handley, the Company's Chief Operating Officer and President, Tivic Biopharma, on February 18, 2025 (the "Inducement Grant"). All share and per share data from the period prior to March 7, 2025 included in this Registration Statement has been retroactively adjusted to reflect the 1-for-17 reverse stock split of the Company's issued and outstanding shares of Common Stock, which was effected on March 7, 2025.

The Inducement Grant was granted outside of the Company's Amended and Restated 2021 Equity Incentive Plan, as amended, as an inducement material to Mr. Handley entering into employment with the Company, was unanimously approved by both the Company's Board of Directors (the "Board") and Compensation Committee of the Board, and was issued pursuant to the "inducement" grant exception under Nasdaq Listing Rule 5635(c)(4).

**PART I**

**INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS**

The information called for in Part I of Form S-8 to be contained in the Section 10(a) prospectus is not being filed with or included in this Registration Statement (by incorporation by reference or otherwise) in accordance with the rules and regulations of the Securities and Exchange Commission (the "Commission"). The documents containing the information specified in Part I of Form S-8 will be delivered to the recipient of the Inducement Grant covered by this Registration Statement, as specified by Rule 428(b)(1) of the Securities Act of 1933, as amended (the "Securities Act").

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

The following documents, which have been filed by the Company with the Commission pursuant to the Securities Exchange Act of 1934, as amended (the "Exchange Act"), are incorporated herein by reference:

· the Company's Annual Report on [Form 10-K](http://www.sec.gov/Archives/edgar/data/1787740/000095017025043234/tivc-20241231.htm) for the fiscal year ended December 31, 2024, filed with the Commission on March 21, 2025 (the "Annual Report");

· the Company's Quarterly Report on [Form 10-Q](http://www.sec.gov/Archives/edgar/data/1787740/000095017025072752/tivc-20250331.htm) filed with the Commission on May 15, 2025; and

· the Company's Current Reports on Form 8-K and 8-K/A filed with the Commission on [January 3, 2025](http://www.sec.gov/Archives/edgar/data/1787740/000095017025001140/tivc-20241227.htm) , [February 5, 2025](http://www.sec.gov/Archives/edgar/data/1787740/000095017025014601/tivc-20250131.htm) , [February 12, 2025](http://www.sec.gov/Archives/edgar/data/1787740/000095017025018419/tivc-20250210.htm) , [February 24, 2025](http://www.sec.gov/Archives/edgar/data/1787740/000095017025025238/tivc-20250218.htm) , [March 5, 2025](http://www.sec.gov/Archives/edgar/data/1787740/000095017025033091/tivc-20250304.htm) , [March 6, 2025](http://www.sec.gov/Archives/edgar/data/1787740/000095017025034191/tivc-20250306.htm) , [March 21, 2025](http://www.sec.gov/Archives/edgar/data/1787740/000095017025043166/tivc-20250318.htm) , [April 3, 2025](http://www.sec.gov/Archives/edgar/data/1787740/000095017025050485/tivc-20250328.htm) , [April 10, 2025](http://www.sec.gov/Archives/edgar/data/1787740/000095017025052679/tivc-20250404.htm) , [April 14, 2025](http://www.sec.gov/Archives/edgar/data/1787740/000095017025053769/tivc-20250414.htm) , [April 22, 2025](http://www.sec.gov/Archives/edgar/data/1787740/000095017025056480/tivc-20250422.htm) , [May 2, 2025](http://www.sec.gov/Archives/edgar/data/1787740/000095017025062733/tivc-20250429.htm) , [May 14, 2025](http://www.sec.gov/Archives/edgar/data/1787740/000095017025070948/tivc-20250509.htm) , [May 20, 2025](http://www.sec.gov/Archives/edgar/data/1787740/000095017025075301/tivc-20250520.htm) , [June 25, 2025](http://www.sec.gov/Archives/edgar/data/1787740/000095017025089741/tivc-20250625.htm) , [July 7, 2025](http://www.sec.gov/Archives/edgar/data/1787740/000095017025094222/tivc-20250630.htm) and [July 25, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/1787740/000095017025098773/tivc-20250618.htm) (provided that any portions of such reports that are deemed furnished and not filed pursuant to
 instructions to Form 8-K shall not be incorporated by reference into this prospectus); and

· the description of the Company's Common Stock contained in the Company's Registration Statement on [Form 8-A](http://www.sec.gov/Archives/edgar/data/1787740/000110465921136539/tm2132372d1_8a12b.htm) filed with the Commission on November 10, 2021 (File No. 001-41052), including any amendment or report filed for the purpose of updating such description, and [Exhibit 4.4](http://www.sec.gov/Archives/edgar/data/1787740/000110465922041068/tm229804d2_ex4-4.htm) of the Annual Report.

All reports and other documents filed by the Company with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items, after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of filing such reports and documents.

Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

**Item 4. Description of Securities.**

Not applicable.

**Item 5. Interests of Names Experts and Counsel.**

Not applicable.

**Item 6. Indemnification of Directors and Officers.**

As permitted by Section 102 of the Delaware General Corporation Law, we have adopted provisions in our amended and restated certificate of incorporation, as amended ("Charter"), and amended and restated bylaws, as amended ("Bylaws"), that limit or eliminate the personal liability of our directors for a breach of their fiduciary duty of care as a director. The duty of care generally requires that, when acting on behalf of the corporation, directors exercise an informed business judgment based on all material information reasonably available to them. Consequently, a director will not be personally liable to us or our stockholders for monetary damages for breach of fiduciary duty as a director, except for liability for:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· any breach of the director's duty of loyalty to us or our stockholders;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· any act or omission not in good faith or that involves intentional misconduct or a knowing violation of
law;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· any act related to unlawful stock repurchases, redemptions or other distributions or payment of dividends;
or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· any transaction from which the director derived an improper personal benefit.

These limitations of liability do not affect the availability of equitable remedies such as injunctive relief or rescission. Our Charter authorizes us to indemnify our officers, directors and other agents to the fullest extent permitted under Delaware law.

As permitted by Section 145 of the Delaware General Corporation Law, our Bylaws provide that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· we may indemnify our directors, officers, and employees to the fullest extent permitted by the Delaware
General Corporation Law, subject to limited exceptions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· we may advance expenses to our directors, officers and employees in connection with a legal proceeding
to the fullest extent permitted by the Delaware General Corporation Law, subject to limited exceptions; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· the rights provided in our Bylaws are not exclusive.

Our Charter provides that we will indemnify each person who was or is a party, or is or was threatened to be made a party, to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of us) by reason of the fact that he or she is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an "Indemnitee"), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. Our Charter provides that we will indemnify any Indemnitee who was or is a party to an action or suit by or in the right of us to procure a judgment in our favor by reason of the fact that the Indemnitee is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys' fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to us, unless a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by us against all expenses (including attorneys' fees) actually and reasonably incurred in connection therewith. Expenses must be advanced to an Indemnitee under certain circumstances.

The above discussion of our Charter, Bylaws and Delaware law is not intended to be exhaustive and is respectively qualified in its entirety by such Charter, Bylaws and applicable Delaware law.

We have entered into indemnification agreements with each of our directors and officers. These indemnification agreements may require us, among other things, to indemnify our directors and officers for certain expenses, including attorneys' fees, judgments, fines and settlement amounts incurred by a director or officer in any action or proceeding arising out of his or her service as one of our directors or officers, or any of our subsidiaries or any other company or enterprise to which the person provides services at our request.

We maintain standard policies of insurance that provide coverage for certain liabilities of directors and officers of our company arising out of claims based on acts or omissions in their capacities as directors or officers.

To the extent that our directors and officers are indemnified under the provisions contained in our Charter, Bylaws, Delaware law or contractual arrangements against liabilities arising under the Securities Act, we have been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act, and is therefore unenforceable.

**Item 7. Exemption from Registration Claimed.**

Not applicable.

**Item 8. Exhibits.**

The exhibits to this Registration Statement are listed in the below Exhibit Index and are incorporated by reference herein.

---

| | |
|:---|:---|
| **Exhibit<br> Number** | **Exhibit Description** |
| 4.1 | [Amended and Restated Certificate of Incorporation of Tivic Health Systems, Inc., dated November 12, 2021](http://www.sec.gov/Archives/edgar/data/1787740/000110465921139122/tm2132951d1_ex3-1.htm) (incorporated by reference to Exhibit 3.1 to the Company's Annual Report on Form 10-K, filed with the Commission on November 15, 2021). |
| 4.2 | [Amended and Restated Bylaws of Tivic Health Systems, Inc.](http://www.sec.gov/Archives/edgar/data/1787740/000110465921139122/tm2132951d1_ex3-2.htm) (incorporated by reference to Exhibit 3.2 to the Company's Annual Report on Form 10-K, filed with the Commission on November 15, 2021). |
| 4.3 | [Certificate of Amendment to the Amended and Restated Bylaws of Tivic Health Systems, Inc., dated July 5, 2023](http://www.sec.gov/Archives/edgar/data/1787740/000095017023032062/tivc-ex3_1.htm) (incorporated by reference to Exhibit 3.3 to the Company's Annual Report on Form 10-K, filed with the Commission on July 6, 2023). |
| 4.4 | [Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Tivic Health Systems, Inc., filed August 21, 2023](http://www.sec.gov/Archives/edgar/data/1787740/000095017023043808/tivc-ex3_1.htm) (effective August 23, 2023) (incorporated by reference to Exhibit 3.4 to the Company's Annual Report on Form 10-K, filed with the Commission on August 22, 2023). |
| 4.5 | [Certificate of Designation of Series A Non-Voting Convertible Preferred Stock of Tivic Health Systems, Inc., dated February 10, 2025](http://www.sec.gov/Archives/edgar/data/1787740/000095017025072752/tivc-ex3_1.htm) (incorporated by reference to Exhibit 3.1 to the Company's Quarterly Report on Form 10-Q, filed with the Commission on May 15, 2025). |
| 4.6 | [Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Tivic Health Systems, Inc., filed March 4, 2025 (effective March 7, 2025)](http://www.sec.gov/Archives/edgar/data/1787740/000095017025033091/tivc-ex3_1.htm) (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K, filed with the Commission on March 5, 2025). |
| 4.7 | [Certificate of Designation of Series B Non-Voting Convertible Preferred Stock of Tivic Health Systems, Inc., dated April 29, 2025](http://www.sec.gov/Archives/edgar/data/1787740/000095017025072752/tivc-ex3_3.htm) (incorporated by reference to Exhibit 3.3 to the Company's Quarterly Report on Form 10-Q, filed with the Commission on May 15, 2025). |
| 5.1\* | [Opinion of Snell & Wilmer L.L.P.](tivic_ex0501.htm) |
| 23.1\* | [Consent of Rosenberg Rich Baker Berman, P.A.](tivic_ex2301.htm) |
| 23.2\* | Consent of Snell & Wilmer L.L.P. (included in [Exhibit 5.1](tivic_ex0501.htm)). |
| 24.1\* | [Power of Attorney](#poa) (included on signature page). |
| 99.1\* | [Restricted Stock Unit Notice of Grant Inducement Grant and Restricted Stock Unit Award Agreement Inducement Grant, dated February 18, 2025](tivic_ex9901.htm). |
| 107\* | [Filing Fee Table](tivic_ex107.htm). |

---

\* Filed herewith

**Item 9. Undertakings.**

(a) The undersigned registrant hereby undertakes:

(1) to file, during any period in which offers or sales are being made, a post-effective amendment to this
Registration Statement:

(i) to include any prospectus required by Section 10(a)(3) of the Securities Act;

(ii) to reflect in the prospectus any facts or events arising after the effective date of this registration
statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change
in the information set forth in this registration statement;

(iii) to include any material information with respect to the plan of distribution not previously disclosed
in this registration statement or any material change to such information in this registration statement; *provided, however*, that
paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the information required to be included in a post-effective
amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13
or Section 15(d) of the Exchange Act that are incorporated by reference in this registration statement;

---

| | |
|:---|:---|
| *provided*, *however*, that paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement. | *provided*, *however*, that paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement. |
| (2) | that, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof; and |
| (3) | to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. |

---

(b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the
Securities Act, each filing of the registrant's annual report pursuant to Section 13(a) or 15(d) of the Exchange
Act that is incorporated by reference in this registration statement shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering
thereof.

(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors,
officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised
that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities
Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by
the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of
any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered,
the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Securities Act and will be
governed by the final adjudication of such issue.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Fremont, State of California on July 25, 2025.

---

| | |
|:---|:---|
| **TIVIC HEALTH SYSTEMS, INC.** | **TIVIC HEALTH SYSTEMS, INC.** |
| By: | /s/ Jennifer Ernst |
|  | Jennifer Ernst |
|  | Chief Executive Officer |

---

**POWER OF ATTORNEY**

Each person whose signatures appear below constitutes and appoints Jennifer Ernst and Lisa Wolf his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 to be filed by Tivic Health Systems, Inc., and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitutes, may lawfully do or cause to be done by virtue hereof.

\*\*\*

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Jennifer Ernst | Chief Executive Officer | July 25, 2025 |
| Jennifer Ernst | (Principal Executive Officer) |  |
| /s/ Lisa Wolf | Chief Financial Officer | July 25, 2025 |
| Lisa Wolf | (Principal Financial and Accounting Officer) |  |
| /s/ Sheryle Bolton | Chair of the Board | July 25, 2025 |
| Sheryle Bolton |  |  |
| /s/ Christina Valauri | Director | July 25, 2025 |
| Christina Valauri |  |  |
| /s/ Dean Zikria | Director | July 25, 2025 |
| Dean Zikria |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

![](image_001.jpg)

July 25, 2025

Tivic Health Systems, Inc.

47685 Lakeview Blvd.

Fremont, CA 94538

**Re: Registration Statement on Form S-8**

Ladies and Gentlemen:

We have acted as counsel to Tivic Health Systems, Inc., a Delaware corporation (the "Company"), in connection with the preparation and filing with the Securities and Exchange Commission (the "Commission") of a Registration Statement on Form S-8 for the registration of 35,295 shares of common stock of the Company, $0.0001 par value per share (the "Shares"), issuable upon vesting and settlement of restricted stock units (the "Inducement Awards"). The Inducement Awards were granted to an employee of the Company outside of a stockholder approved equity incentive plan as an inducement material to entry into employment of such employee with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4).

This opinion is being furnished in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act in connection with the filing of the Registration Statement, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or the related prospectus, other than as expressly stated herein with respect to the issuance of the Shares.

In connection with this letter, we have examined originals, or copies certified or otherwise identified to our satisfaction, of (i) the Amended and Restated Certificate of Incorporation of the Company, as amended, as currently in effect, (ii) the Amended and Restated Bylaws of the Company, as amended, as currently in effect, (iii) the Restricted Stock Unit Notice of Grant Inducement Grant and Restricted Stock Unit Award Agreement Inducement Grant, dated February 18, 2025 (together, the "Inducement Award Agreement"), related to the Inducement Awards, (iv) the Registration Statement, (v) a certificate executed by an officer of the Company, dated as of the date hereof, as to certain factual matters, and (vi) such other corporate documents and records as we deemed appropriate for purposes of the opinions set forth herein. For the purpose of rendering this opinion, we have made such factual and legal examinations as we deemed necessary under the circumstances, and in that connection therewith we have examined, among other things, originals or copies, certified or otherwise identified to our satisfaction, of such documents, corporate records, certificates of public officials, certificates of officers or other representatives of the Company, and other instruments and have made such inquiries as we have deemed appropriate for the purpose of rendering this opinion.

In our examination, we have assumed without independent verification the legal capacity of all natural persons, the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as facsimile, electronic, certified, conformed or photostatic copies, and the authenticity of the originals of such copies. In making our examination of executed documents, we have assumed that the parties thereto, other than the Company, had the power, corporate or other, to enter into and perform all obligations thereunder and have also assumed the due authorization by all requisite action, corporate or other, and the execution and delivery by such parties of such documents and the validity and binding effect thereof on such parties. Our opinions are subject to applicable bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and similar laws affecting creditors' rights and remedies generally, and subject, as to enforceability, to general principles of equity, including principles of commercial reasonableness, good faith and fair dealing (regardless of whether enforcement is sought in a proceeding at law or in equity). As to any facts material to the opinions expressed herein which were not independently established or verified, we have relied upon oral or written statements and representations of officers or other representatives of the Company and others.

![](image_001.jpg)

On the basis of, and in reliance on, the foregoing examination and subject to the assumptions, exceptions, qualifications and limitations contained herein, we are of the opinion that the Shares have been duly authorized and, when issued in accordance with the terms of the Inducement Award Agreement, will be validly issued, fully paid and non-assessable.

The opinion expressed herein is limited to the Delaware General Corporation Law and reported judicial decisions applicable thereto. We neither express nor imply any obligation with respect to any other laws or the laws of any other jurisdiction or of the United States. For purposes of this opinion, we assume that the Shares will be issued in compliance with all applicable state securities or blue sky laws.

We assume no obligation to update or supplement this opinion if any applicable laws change after date of this opinion or if we become aware after the date of this opinion of any facts, whether existing before or arising after the date hereof, that might change the opinions expressly so stated. Without limiting the generality of the foregoing, we neither express nor imply any opinion regarding the contents of the Registration Statement, other than as expressly stated herein with respect to the Shares.

We are opining only as to matters expressly set forth herein, and no opinion should be inferred as to any other matters. This opinion is rendered as of the date hereof and is based upon currently existing statutes, rules, regulations and judicial decisions. We disclaim any obligation to advise you of any change in any of these sources of law or subsequent legal or factual developments that affect any matters or opinions set forth herein.

We hereby consent to the filing of this opinion letter with the Commission as Exhibit 5.1 to the Registration Statement filed by the Company. In giving such consent, we do not thereby concede that we are included in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.

Very truly yours,

<u>/s/ Snell & Wilmer L.L.P.</u>

Snell & Wilmer L.L.P.

## Exhibit 23.1

**Exhibit 23.1**

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated March 21, 2025 (which includes an explanatory paragraph relating to Tivic Health Systems, Inc.'s ability to continue as a going concern) relating to the financial statements of Tivic Health Systems, Inc. as of and for the years ended December 31, 2024 and 2023.

/s/ Rosenberg Rich Baker Berman, P.A.

Somerset, New Jersey

July 25, 2025

## Exhibit 99.1

**Exhibit 99.1**

**Tivic Health Systems, Inc.<br> Restricted Stock Unit Notice of Grant<br> Inducement Grant**

**FOR GOOD AND VALUABLE CONSIDERATION**, Tivic Health Systems, Inc., a Delaware corporation (the "**Company**"), hereby grants to the Participant named below, an Award of Restricted Stock Units (the "**RSU Award**"), upon the terms and subject to the conditions set forth in that Employment Agreement entered into by and between the Company and the Participant named below on February 18, 2025 (the "**Employment Agreement**") and this Restricted Stock Unit Notice of Grant (the "**Grant Notice**"). The RSU Award has been granted as an "inducement" award under the Nasdaq Listing Rule 5635(c)(4) pursuant to the Employment Agreement and the Restricted Stock Unit Award Agreement (the "**<u>RSU Award Agreement</u>**") attached hereto, and has been granted outside of the Company's Amended and Restated 2021 Equity Incentive Plan (as may be amended from time to time, the "**<u>Plan</u>**") or any other established equity incentive plan of the Company. Notwithstanding the foregoing, the RSU Award shall be subject to the same terms as set forth in the Plan and will be governed in all respects as though it were issued under the Plan, and unless otherwise defined herein, the terms defined in the Plan will have the same defined meanings in this Grant Notice.

---

| | |
|:---|:---|
| Participant: | Michael Handley<br>|
| Date of Grant: | February 18, 2025<br>|
| Vesting Commencement Date: | February 18, 2025<br>|
| Number of Restricted Stock Units: | 600,000<br>|

---

**1. Vesting Schedule**: Subject to any acceleration provisions contained in the Employment Agreement, RSU Agreement or set forth below, the Restricted Stock Units subject to this RSU Award (the "**Restricted Stock Units**") will vest in accordance with the following schedule: (i) no Restricted Stock Units will be vested prior to the Vesting Commencement Date; (ii) twenty-five percent (25%) of the Restricted Stock Units will vest upon the one (1) year anniversary of the Vesting Commencement Date, provided that there has not been a Termination of Service as of such date; and (iii) the balance of the Restricted Stock Units will be vested in a series of twelve (12) successive equal quarterly installments measured from the first anniversary of the Vesting Commencement Date such that 100% of the Restricted Stock Units shall have vested on the fourth anniversary of the Vesting Commencement Date, provided that there has not been a Termination of Service as of each such date.

In no event will any portion of the Restricted Stock Units vest after a Termination of Service, and the Restricted Stock Units and Participant's right to acquire any Shares hereunder will immediately terminate upon a Termination of Service.

**2. Change in Control**. Notwithstanding the provisions of Section 1 hereof, in the event of a Change in Control (as defined in the Plan):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Provided that there has not been a Termination of Services as of such date, the right to receive Shares under the Restricted Stock Units shall accelerate automatically and vest in full, and the Restricted Stock Units shall become vested as to all of the Restricted Stock Units, effective as of immediately prior to the consummation of the Change in Control (as defined in the Plan) <u>unless</u> the Restricted Stock Units are to be assumed by the acquiring or successor entity (or parent thereof) or new Restricted Stock Units or New Incentives are to be issued in exchange therefor, as provided in Section 2(b) below. If the vesting of the Restricted Stock Units will accelerate pursuant to this Section 2(a), then the Board shall cause written notice of the Change in Control transaction to be given to the Participant not less than fifteen (15) days prior to the anticipated effective date of the proposed transaction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)The vesting of the Restricted Stock Units <u>shall not</u> accelerate if and to the extent that: (i) the Restricted Stock Units (including the unvested portion thereof) are to be assumed by the acquiring or successor entity (or parent thereof) or a new Restricted Stock Units of comparable value is to be issued in exchange therefor pursuant to the terms of the Change in Control transaction, or (ii) the Restricted Stock Units (including the unvested portion thereof) are to be replaced by the acquiring or successor entity (or parent thereof) with other incentives of comparable value under a new incentive program ("<u>New Incentives</u>") containing such terms and provisions as the Board in its discretion may consider equitable. If the Restricted Stock Units are assumed, or if new Restricted Stock Units of comparable value are issued in exchange therefor, then the Restricted Stock Units or the new Restricted Stock Units shall be appropriately adjusted, concurrently with the Change in Control, to apply to the number and class of securities or other property that the Participant would have received pursuant to the Change in Control transaction in exchange for the Shares issuable upon settlement of the Restricted Stock Units had the Restricted Stock Units vested immediately prior to the Change in Control.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)If the provisions of Section 2(b) above apply, then the Restricted Stock Units, the new Restricted Stock Units or the New Incentives shall continue to vest in accordance with the provisions of Section 1 hereof and shall continue in effect for the remainder of the term of the Restricted Stock Units in accordance with the provisions hereof. However, in the event of an Involuntary Termination (as defined below), which results in Participant's Termination of Service, within twelve (12) months following such Change in Control, then vesting of the Restricted Stock Units, the new Restricted Stock Units or the New Incentives, as applicable, shall accelerate in full automatically effective upon such Involuntary Termination.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)"**Involuntary Termination**" shall mean Participant's Termination of Service by reason of:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)Participant's involuntary dismissal or discharge by the Company, or by the acquiring or successor entity (or parent or any subsidiary thereof employing the Participant) for reasons other than Cause (as defined in the Restricted Stock Unit Agreement), or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)Participant's voluntary resignation following (x) the assignment to Participant of any authority, duties or responsibilities or the reduction of Participant's authority, duties or responsibilities, either of which results in a material diminution in Participant's authority, duties or responsibilities at the Company; (y) a material reduction of 20% or more by the Company in Participant's base salary, other than a one-time reduction that is applicable to substantially all other similarly-situated executives; or (y) except as otherwise herein contemplated, a non-temporary relocation of Participant's principal work location office to a location that increases Participant's one way commute from Participant's principal residence by more than 50 miles; provided, however, that any resignation by Participant due to any of the foregoing conditions specified in this clause (B) shall only be deemed an Involuntary Termination if: (i) Participant gives the Company written notice within 60 days after Participant knows or should know of the initial existence of such event or action, (ii) such event or action is not reversed, remedied or cured, as the case may be, by the Company as soon as possible but in no event later than 30 days of receiving such written notice from Participant, and (iii) Participant terminates employment within 60 days following the end of the cure period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)The provisions of this Section shall not limit the grounds for the dismissal or discharge of Participant or any other individual in the service of the Company, the acquiring or successor entity (or parent or any subsidiary thereof).

**Additional Terms/Acknowledgements:** The undersigned Participant acknowledges receipt of, and understands and agrees to, this Grant Notice, the RSU Award Agreement, the Employment Agreement, and the Plan.

Further, by their signatures below, the Company and the Participant agree that the RSU Award is governed by this Grant Notice, the Employment Agreement, and by the provisions of the Plan (despite the fact that the RSU Award was granted outside of the Plan) and the RSU Award Agreement, both of which are attached to and made a part of this Grant Notice. Participant acknowledges receipt of copies of the Plan and the RSU Award Agreement, represents that the Participant has read and is familiar with their provisions, and hereby accepts the RSU Award subject to all of their terms and conditions. Participant further acknowledges that, as of the Date of Grant, this Grant Notice, the Employment Agreement the RSU Award Agreement and the Plan set forth the entire understanding between Participant and the Company regarding the RSU Award and supersede all prior oral and written agreements on that subject.

**\*Participant understands and acknowledges that the vesting of the Restricted Stock Units will terminate upon a Termination of Service (as defined in the Plan).**

[*Signatures on following page*]

---

| | | | |
|:---|:---|:---|:---|
| **Tivic Health Systems, Inc.** | **Tivic Health Systems, Inc.** | **Participant: Michael Handley** | **Participant: Michael Handley** |
| By: | /s/ Lisa Wolf | /s/ Michael Handley | /s/ Michael Handley |
|  | Lisa Wolf, Interim CFO | Signature | Signature |
| Date: | February 18, 2025 | Date: | February 18, 2025 |
|  |  | Address: |  |

---

---

| | |
|:---|:---|
| **Attachments**: | (I) Restricted Stock Unit Award Agreement |
|  | (II) Amended and Restated 2021 Equity Incentive Plan |

---

**<u>Attachment I</u>**

**Tivic Health Systems, Inc.<br> Restricted Stock Unit Award Agreement**

**Inducement Grant**

As reflected by the Restricted Stock Unit Notice of Grant ("**Grant Notice**") that Employment Agreement entered into by and between Tivic Health Systems, Inc., a Delaware Corporation (the "**Company**"), and the Participant on February 18, 2025 (the "**Employment Agreement**"), the Grant Notice and this Restricted Stock Award Agreement (the "**Award Agreement**"), the Company has granted to Participant an RSU Award for the number of restricted stock units as indicated in the Grant Notice (the "**RSU Award**"). The RSU Award has been granted as an "inducement" award under the Nasdaq Listing Rule 5635(c)(4), and has been granted outside of the Company's Amended and Restated 2021 Equity Incentive Plan (as may be amended from time to time, the "**Plan**") or any other established equity incentive plan of the Company. Notwithstanding the foregoing, the RSU Award shall be subject to the same terms as set forth in the Plan and will be governed in all respects as though it were issued under the Plan. The terms of the RSU Award as specified in the Grant Notice, the Employment Agreement and this Restricted Stock Unit Award Agreement constitute the "**Award Agreement**." Defined terms not explicitly defined herein but defined in the Grant Notice or the Plan shall have the same definitions as in the Grant Notice or Plan, as applicable.

The general terms applicable to the RSU Award are as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.<u>Governing Plan Documents</u>.** Participant's RSU Award is subject to all the provisions of the Plan (despite the fact that the RSU Award was granted outside of the Plan), including but not limited to the provisions in:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Section 6(c) of the Plan regarding the award, issuance and settlement of Restricted Stock Units;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Section 11 of the Plan regarding adjustments upon a Change in Control; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Section 13(c) of the Plan regarding the Company's retained rights to terminate Participant's employment or other services to the Company notwithstanding the grant of the RSU Award.

The RSU Award is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan. In the event of any conflict between the RSU Award Agreement and the provisions of the Plan, the provisions of the RSU Award Agreement shall control.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.<u>Grant of RSU Award</u>.** This RSU Award represents Participant's right to be issued on a future date the number of shares of the Company's Common Stock that is equal to the number of restricted stock units indicated in the Grant Notice, subject to any adjustments as provided in the Plan and Participant's satisfaction of the vesting conditions set forth therein (the "**Restricted Stock Units**"). Any additional Restricted Stock Units that become subject to the RSU Award, as set forth in the Plan and the provisions of Section 4 below, if any, shall be subject, in a manner determined by the Board, to the same forfeiture restrictions, restrictions on transferability, and time and manner of delivery as applicable to the other Restricted Stock Units covered by the RSU Award.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.<u>Vesting</u>.** Participant's Restricted Stock Units will vest, if at all, in accordance with the vesting schedule provided in the Grant Notice, subject to the provisions contained herein and the terms of the Plan. Except as otherwise set forth in the Employment Agreement, vesting will cease upon a Termination of Service.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.<u>Dividends</u>.** Except as may otherwise be provided in the Plan, Participant may become entitled to receive payments equal to any cash dividends and other distributions paid with respect to a corresponding number of shares of Common Stock to be issued in respect of the Restricted Stock Units covered by the RSU Award. Any such dividends or distributions shall be subject to the same forfeiture restrictions as apply to the Restricted Stock Units and shall be paid at the same time that the corresponding shares are issued in respect of Participant's vested Restricted Stock Units, provided, however that to the extent any such dividends or distributions are paid in shares of Common Stock, then Participant will automatically be granted a corresponding number of additional Restricted Stock Units subject to the RSU Award (the "**Dividend Units**"), and further provided that such Dividend Units shall be subject to the same forfeiture restrictions and restrictions on transferability, and same timing requirements for issuance of shares, as apply to the Restricted Stock Units subject to the RSU Award with respect to which the Dividend Units relate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.<u>Withholding Obligations</u>.** As further provided in Section 13(g) of the Plan, the Company shall have the right to withhold or otherwise require Participant to remit to the Company an amount sufficient to satisfy federal, state and local withholding tax requirements (the "**Withholding Obligation**") prior to delivery of any Common Stock in respect of the RSU Award. In the event the that the amount of the Withholding Obligation is greater than the amount withheld by the Company, Participant agrees to indemnify and hold the Company harmless from any failure by the Company to withhold the proper amount.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.<u>Date of Issuance</u>.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)The issuance of shares in respect of the Restricted Stock Units is intended to comply with Treasury Regulations Section 1.409A-1(b)(4) and will be construed and administered in such a manner. Subject to the satisfaction of the Withholding Obligation, if any, in the event one or more Restricted Stock Units vests, the Company shall issue to Participant one (1) share of Common Stock for each Restricted Stock Unit that vests on the applicable vesting date(s) (subject to any adjustment under Section 4 above, and subject to any different provisions in the Grant Notice). Each issuance date determined by this paragraph is referred to as an "**Original Issuance Date**."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)If the Original Issuance Date falls on a date that is not a business day, delivery shall instead occur on the next following business day. In addition, if:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)the Original Issuance Date does not occur (1) during an "open window period" applicable to Participant, as determined by the Company in accordance with the Company's then-effective policy on trading in Company securities, or (2) on a date when Participant is otherwise permitted to sell shares of Common Stock on an established stock exchange or stock market (including but not limited to under a previously established written trading plan that meets the requirements of Rule 10b5-1 under the Exchange Act and was entered into in compliance with the Company's policies (a "**10b5-1 Arrangement**)), *and*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)either (1) a Withholding Obligation does not apply, or (2) the Company decides, prior to the Original Issuance Date, (A) not to satisfy the Withholding Obligation by withholding shares of Common Stock from the shares otherwise due, on the Original Issuance Date, to Participant under this Award, and (B) not to permit Participant to enter into a "same day sale" commitment with a broker-dealer (including but not limited to a commitment under a 10b5-1 Arrangement) and (C) not to permit Participant to pay the Withholding Obligation in cash,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)<u>then</u> the shares that would otherwise be issued to Participant on the Original Issuance Date will not be delivered on such Original Issuance Date and will instead be delivered on the first business day when Participant is not prohibited from selling shares of the Company's Common Stock in the open public market or on such other date determined by the Company, but in no event later than December 31 of the calendar year in which the Original Issuance Date occurs (that is, the last day of Participant's taxable year in which the Original Issuance Date occurs), or, <u>if and only if</u> permitted in a manner that complies with Treasury Regulations Section 1.409A-1(b)(4), no later than the date that is the 15th day of the third calendar month of the applicable year following the year in which the shares of Common Stock under this Award are no longer subject to a "substantial risk of forfeiture" within the meaning of Treasury Regulations Section 1.409A-1(d).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**7.<u>Transferability</u>.** Except as otherwise provided in the Plan, Participant's RSU Award is not transferable, except by will or by the applicable laws of descent and distribution.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.<u>Company Not Liable for Taxes</u>**. As a condition to accepting the RSU Award, Participant hereby (a) agrees to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from the RSU Award or other Company compensation and (b) acknowledges that Participant was advised to consult with Participant's own personal tax, financial and other legal advisors regarding the tax consequences of the RSU Award and have either done so or knowingly and voluntarily declined to do so.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9.<u>Miscellaneous</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)This Award Agreement shall bind and inure to the benefit of the parties' heirs, legal representatives, successors and permitted assigns.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Employment Agreement, this Award Agreement, the Grant Notice and the terms of the Plan (despite the fact that the RSU Award was granted outside of the Plan), constitute the entire agreement between the parties pertaining to the subject matter contained herein and they supersede all prior and contemporaneous agreements, representations and understandings of the parties with respect to the subject matter hereof. No supplement, modification or amendment of this Award Agreement shall be binding unless executed in writing by all of the parties. No waiver of any of the provisions of this Award Agreement shall be deemed or shall constitute a waiver of any other provisions, whether or not similar, nor shall any waiver constitute a continuing waiver. No waiver shall be binding unless executed in writing by the party making the waiver. In the event there exists any conflict or discrepancy between any of the terms in the Plan and this Award Agreement, the terms of the this Award Agreement shall be controlling. A copy of the Plan has been delivered to Participant and also may be inspected by Participant at the principal office of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Should any portion of the Employment Agreement, the Plan, the Grant Notice or this Award Agreement be declared invalid and unenforceable, then such portion shall be deemed to be severable from this Award Agreement and shall not affect the remainder hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified; (ii) three (3) days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iii) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt; or (iv) the same day if sent via electronic means (including via fax or email) before close of business on that day, or the next business day if sent on a weekend or after close of business on that day. All communications shall be sent to the Company at its principal executive office, and to Participant at the address set forth in the Company's records, or at such other address as the Company or Participant may designate by ten (10) days advance written notice to the other party hereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) This Award Agreement shall be construed according to the laws of the State of Delaware.

[Remainder of Page Intentionally Left Blank]

**Attachment II**

**Amended and Restated 2021 Equity Incentive Plan**

## Ex-Filing

**Exhibit 107**

**CALCULATION OF FILING FEE TABLES**

Form S-8

**(Form Type)**

Tivic Health Systems, Inc.

**(Exact Name of Registrant as Specified in its Charter)**

<u>Table 1: Newly Registered Securities</u>

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | Security<br> Type | Security Class Title | Fee<br> Calculation<br> or Carry<br> Forward<br> Rule | Amount<br> Registered (1) | Proposed<br> Maximum<br> Offering<br> Price Per<br> Share | Proposed<br> Maximum<br> Aggregate<br> Offering<br> Price | Fee Rate | Amount of<br> Registration<br> Fee |
| Newly Registered Securities | Newly Registered Securities | Newly Registered Securities | Newly Registered Securities | Newly Registered Securities | Newly Registered Securities | Newly Registered Securities | Newly Registered Securities | Newly Registered Securities |
| Fees to be<br> Paid | Equity | Common Stock,<br> $0.0001 par<br> value per<br> share | Rule 457(h); Rule 457(c) | 35295(2) | $4.07(3) | $143650.65 | $0.00015310 | $21.99 |
| Fees<br> Previously<br> Paid |  |  |  |  |  |  |  |  |
| Carry Forward Securities | Carry Forward Securities | Carry Forward Securities | Carry Forward Securities | Carry Forward Securities | Carry Forward Securities | Carry Forward Securities | Carry Forward Securities | Carry Forward Securities |
| Carry<br> Forward<br> Securities |  |  |  |  |  |  |  |  |
|  | Total Offering Amounts | Total Offering Amounts | Total Offering Amounts | Total Offering Amounts |  |  |  | $21.99 |
|  | Total Fees Previously Paid | Total Fees Previously Paid | Total Fees Previously Paid | Total Fees Previously Paid |  |  |  | - |
|  | Total Fees Offsets | Total Fees Offsets | Total Fees Offsets | Total Fees Offsets |  |  |  | - |
|  | Net Fee Due | Net Fee Due | Net Fee Due | Net Fee Due |  |  |  | $21.99 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "Securities
Act"), this Registration Statement shall also cover any additional shares of common stock, par value $0.0001 per share ("Common
Stock"), of Tivic Health Systems, Inc. (the "Company") that become issuable by reason of any stock dividend, stock split,
recapitalization or other similar transaction effected without receipt of consideration that increases the number of outstanding shares
of Common Stock.

&nbsp;&nbsp;&nbsp;&nbsp;(2) Represents 35,295 shares of Common Stock of the Company issuable upon vesting and
settlement of Restricted Stock Units ("RSUs") granted to Michael Handley, the Company's Chief Operating Officer and
President, Tivic Biopharma, on February 18, 2025. Such RSUs were granted outside of the Company's Amended and Restated 2021 Equity
Incentive Plan, as amended, as an inducement material to Mr. Handley entry into employment with the Company, in accordance with Nasdaq
Listing Rule 5635(c)(4).

&nbsp;&nbsp;&nbsp;&nbsp;(3) Estimated solely for the purpose of calculating the amount of the registration
fee in accordance with Rules 457(c) and 457(h) of the Securities Act. The proposed maximum offering price per share is based upon the
average of the high and low prices of the Company's Common Stock, as reported on the Nasdaq Capital Market on July 18, 2025, a date
within five business days prior to the filing of the Registration Statement.